NCT04446000View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions
Immune Complex-mediated Autoimmune Diseases
Interventions
BIOLOGICAL

CSL730

solution for injection and infusion

DRUG

Placebo

A solution matching the excipient profile of CSL730 without the active substance

Trial Locations (1)

HA1 3UJ

PAREXEL Early Phase Clinical Unit (London), Northwick Park Hospital, Harrow

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY